Buparlisib (codenamed AN2025 and BKM120) is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide...
8 KB (690 words) - 22:44, 5 August 2024
clinical trials: Buparlisib (codenamed BKM120, NVP-BKM120; pan-class I PI3K inhibitor): The phase III trial BURAN compares buparlisib + paclitaxel to paclitaxel...
45 KB (5,359 words) - 22:07, 19 July 2024
ivosidenib -lisib Phosphatidylinositol 3-kinase inhibitors alpelisib, buparlisib -parib PARP inhibitor olaparib, veliparib -rafenib BRAF inhibitors sorafenib...
26 KB (2,150 words) - 07:07, 12 June 2024
another pan-PI3K inhibitor with greater subunitĪ±-inhibitor activity than buparlisib. Idelalisib is the first PI3K inhibitor approved by the US Food and Drug...
36 KB (4,322 words) - 11:55, 11 August 2024